AR109931A1 - Compuesto inhibidor de la prostaglandina d sintasa hematopoyética (h-pgds), composición farmacéutica que lo comprende y uso del compuesto para fabricar un medicamento - Google Patents
Compuesto inhibidor de la prostaglandina d sintasa hematopoyética (h-pgds), composición farmacéutica que lo comprende y uso del compuesto para fabricar un medicamentoInfo
- Publication number
- AR109931A1 AR109931A1 ARP170102843A ARP170102843A AR109931A1 AR 109931 A1 AR109931 A1 AR 109931A1 AR P170102843 A ARP170102843 A AR P170102843A AR P170102843 A ARP170102843 A AR P170102843A AR 109931 A1 AR109931 A1 AR 109931A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- fluoro
- oxo
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto inhibidor de la prostaglandina D sintasa hematopoyética (H-PGDS) que está representado por la fórmula (1), en donde: X se selecciona de: carbono y nitrógeno; Y se selecciona de: hidrógeno y CH₃; Y¹ está ausente o CH₃; Z es NH u O; a es 0 ó 1; R se selecciona de: O, NH, CH₂ y alquilo C₁ sustituido con halógeno; R¹ se selecciona de: arilo, arilo sustituido de 1 a 4 veces con Rᵃ, heteroarilo, heteroarilo sustituido de 1 a 4 veces con Rᵃ, bicicloheteroarilo, y bicicloheteroarilo sustituido de 1 a 4 veces con Rᵃ; R² se selecciona de: O y S; R³ se selecciona de: arilo, arilo sustituido de 1 a 4 veces con Rᵇ, cicloalquilo, cicloalquilo sustituido de 1 a 4 veces con Rᵇ, heterociclo, heterociclo sustituido de 1 a 4 veces con Rᵇ, heteroarilo, heteroarilo sustituido de 1 a 4 veces con Rᵇ, bicicloheteroarilo, y bicicloheteroarilo sustituido de 1 a 4 veces con Rᵇ; cada Rᵃ se selecciona independientemente de: fluoro, cloro, bromo, yodo, -OH, alquilo C₁₋₆, alquilo C₁₋₆ sustituido con 1 a 5 sustituyentes independientemente seleccionados de: fluoro, cloro, bromo, yodo, alquiloxi C₁₋₄, -OH, alquilo C₁₋₄, oxo, -COOH, -NO₂, -NH₂ y -CN, ciano, -O-alquilo C₁₋₆, -O-alquilo C₁₋₆ sustituido con 1 a 5 sustituyentes independientemente seleccionados de: fluoro, cloro, bromo, yodo, alquiloxi C₁₋₄, -OH, alquilo C₁₋₄, oxo, -COOH, -NO₂, -NH₂ y -CN, -C(O)O-alquilo C₁₋₆, y -C(O)O-alquilo C₁₋₆ sustituido de 1 a 5 veces con fluoro; cada Rᵇ se selecciona independientemente de: ciano, fluoro, cloro, bromo, yodo, alquilo C₁₋₆, Rᵉ, -O-alquilo C₁₋₆, -ORᵉ, oxo, hidroxilo, cicloalquilo, cicloalquilo sustituido de 1 a 4 veces con Rᶠ, amino, -NHRˣ, donde Rˣ se selecciona de arilo, heteroarilo, cicloalquilo, heterocicloalquilo, -O-alquilo C₁₋₆, -O-alquilo C₁₋₆ sustituido con de 1 a 6 sustituyentes independientemente seleccionados de: fluoro, oxo, y -OH, alquilo C₁₋₆, y alquilo C₁₋₆ sustituido con de 1 a 6 sustituyentes independientemente seleccionados de: fluoro, oxo, -OH, -OC₁₋₆alquilo, -COOH, -NH₂, -NH-cicloalquilo, y -CN, heteroarilo, heteroarilo sustituido de 1 a 4 veces con Rᶠ, heterociclo, heterociclo sustituido de 1 a 4 veces con Rᶠ, -SO₂H, y -SO₂-alquilo C₁₋₆; cada Rᶠ se selecciona independientemente de: fluoro, cloro, bromo, yodo, alquilo C₁₋₆, Rᵉ, oxo, -OH, amino, -NHRˣ¹, donde Rˣ¹ se selecciona de arilo, heteroarilo, cicloalquilo, heterocicloalquilo, alquilo C₁₋₆, y alquilo C₁₋₆ sustituido con de 1 a 6 sustituyentes independientemente seleccionados de: fluoro, oxo, -OH, -O-alquilo C₁₋₆, -COOH, -NH₂, y -CN, -NRˣ²Rˣ³, donde Rˣ² y Rˣ³ se selecciona uno independientemente de: arilo, heteroarilo, cicloalquilo, heterocicloalquilo, alquilo C₁₋₆, y alquilo C₁₋₆ sustituido con 1 a 6 sustituyentes independientemente seleccionados de: fluoro, oxo, -OH, -COOH, -NH₂, y -CN, nitro, y ciano, y cada Rᵉ se selecciona independientemente de: alquilo C₁₋₆ sustituido con 1 a 9 sustituyentes independientemente seleccionados de: fluoro, cloro, bromo, yodo, alquilo C₁₋₆, -O-alquilo C₁₋₆, -O-alquilo C₁₋₆ sustituido con 1 a 6 sustituyentes independientemente seleccionados de: fluoro, oxo, -OH, -COOH, -NH₂, -CN, y fenilo, oxo, =N, hidroxilo, amino, -NHRˣˣ, o =NRˣˣ, donde Rˣˣ se selecciona de arilo, heteroarilo, cicloalquilo, heterocicloalquilo, ciano, alquilo C₁₋₆, y alquilo C₁₋₆ sustituido con 1 a 6 sustituyentes independientemente seleccionados de: fluoro, oxo, -OH, -COOH, -O-C₁₋₅ alquilo, -O-alquilo C₁₋₅ sustituido de 1 a 6 veces con fluoro, -NRˣˣ¹Rˣˣ², donde Rˣˣ¹ y Rˣˣ² se selecciona cada uno independientemente de: arilo, heteroarilo, cicloalquilo, heterocicloalquilo, alquilo C₁₋₆, y alquilo C₁₋₆ sustituido con 1 a 6 sustituyentes independientemente seleccionados de: fluoro, oxo, -OH, -COOH, -NH₂, y -CN, arilo, arilo sustituido de 1 a 4 veces con Rˣˣ³, donde Rˣˣ³ se selecciona de: fluoro, cloro, bromo, yodo, alquilo C₁₋₆, alquilo C₁₋₆ sustituido con 1 a 6 sustituyentes independientemente seleccionados de: fluoro, oxo, -OH, -COOH, -NH₂, y -CN, -O-alquilo C₁₋₅, y -O-alquilo C₁₋₆ sustituido con 1 a 6 independientemente sustituyentes seleccionados de: fluoro, oxo, -OH, -COOH, -NH₂, y -CN, cicloalquilo, cicloalquilo sustituido de 1 a 4 veces con Rˣˣ⁴, donde Rˣˣ⁴ se selecciona de: fluoro, cloro, bromo, yodo, alquilo C₁₋₆, alquilo C₁₋₆ sustituido con 1 a 6 sustituyentes independientemente seleccionados de: fluoro, oxo, -OH, -COOH, -NH₂, y -CN, -O-alquilo C₁₋₅, y -O-alquilo C₁₋₆ sustituido con 1 a 6 independientemente sustituyentes seleccionados de: fluoro, oxo, -OH, -COOH, -NH₂, y -CN, nitro, y ciano; o una de sus sales farmacéuticamente aceptables. Los compuestos descritos pueden ser útiles en el tratamiento de la distrofia muscular de Duchenne. Composiciones farmacéuticas que comprenden los compuestos descritos y uso de los compuestos para fabricar un medicamento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662407634P | 2016-10-13 | 2016-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109931A1 true AR109931A1 (es) | 2019-02-06 |
Family
ID=60320926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102843A AR109931A1 (es) | 2016-10-13 | 2017-10-11 | Compuesto inhibidor de la prostaglandina d sintasa hematopoyética (h-pgds), composición farmacéutica que lo comprende y uso del compuesto para fabricar un medicamento |
Country Status (24)
Country | Link |
---|---|
US (1) | US11053234B2 (es) |
EP (1) | EP3526206A1 (es) |
JP (1) | JP6938628B2 (es) |
KR (1) | KR20190072565A (es) |
CN (1) | CN110072857A (es) |
AR (1) | AR109931A1 (es) |
AU (1) | AU2017342156B2 (es) |
BR (1) | BR112019007609A2 (es) |
CA (1) | CA3038756A1 (es) |
CL (1) | CL2019000986A1 (es) |
CO (1) | CO2019003482A2 (es) |
CR (1) | CR20190174A (es) |
DO (1) | DOP2019000087A (es) |
EA (1) | EA201990904A1 (es) |
IL (1) | IL265597A (es) |
JO (1) | JOP20190072A1 (es) |
MA (1) | MA46531A (es) |
MX (1) | MX2019004320A (es) |
PE (1) | PE20191020A1 (es) |
PH (1) | PH12019500811A1 (es) |
TW (1) | TW201827412A (es) |
UY (1) | UY37440A (es) |
WO (1) | WO2018069863A1 (es) |
ZA (1) | ZA201901848B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
BR112019026452A2 (pt) * | 2017-06-13 | 2020-07-14 | Glaxosmithkline Intellectual Property Development Limited | compostos químicos como inibidores de h-pgds |
KR20200037830A (ko) * | 2017-08-09 | 2020-04-09 | 데날리 테라퓨틱스 인크. | 화합물, 조성물 및 방법 |
MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
TW202045164A (zh) | 2019-02-13 | 2020-12-16 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
WO2021152113A1 (en) | 2020-01-31 | 2021-08-05 | Bayer Aktiengesellschaft | Substituted 2,3-benzodiazepines derivatives |
WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
CN113582880B (zh) * | 2020-04-30 | 2023-11-17 | 南京药石科技股份有限公司 | 一种(3-氨基二环[1.1.1]戊烷-1-基)氨基甲酸叔丁酯的制备方法 |
CN111574473A (zh) * | 2020-06-04 | 2020-08-25 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 一种氨基噻唑类化合物的合成方法 |
CN111549000B (zh) * | 2020-06-18 | 2022-07-29 | 中国医学科学院整形外科医院 | 一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用 |
JPWO2021256569A1 (es) | 2020-06-19 | 2021-12-23 | ||
CN114085167A (zh) * | 2021-12-13 | 2022-02-25 | 华中药业股份有限公司 | 一种杂质ts-3a的制备方法 |
JPWO2023113023A1 (es) | 2021-12-17 | 2023-06-22 | ||
WO2023201014A1 (en) * | 2022-04-15 | 2023-10-19 | Vanderbilt University | Benzothiazole-phenylsulfonyl-piperidine analogs as activators of n-acylphosphatidylethanolamine hydrolyzing phospholipase d |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4031221A (en) * | 1974-06-17 | 1977-06-21 | American Hoechst Corporation | Method of treating pain and hypertension |
US4956359A (en) | 1985-02-28 | 1990-09-11 | A. H. Robins Company, Inc. | 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics |
IE58943B1 (en) | 1985-02-28 | 1993-12-01 | Robins Co Inc A H | 3-Aryloxy-azetidine-carboxamides |
US6809088B2 (en) * | 1997-03-24 | 2004-10-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
GB9801501D0 (en) * | 1998-01-23 | 1998-03-18 | Cerebrus Ltd | Chemical compounds - II |
GB9917385D0 (en) | 1999-07-23 | 1999-09-22 | Cerebrus Ltd | Chemical compounds-I |
US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
CA2556239A1 (en) * | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2005094805A1 (ja) | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
BRPI0510340A (pt) * | 2004-04-28 | 2007-10-30 | Pfizer | derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina |
AP2007004047A0 (en) * | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
JP2008545008A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
GB0514017D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンd合成酵素を阻害するピリミジン化合物 |
PE20110118A1 (es) * | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
US20070208426A1 (en) * | 2006-03-03 | 2007-09-06 | Sdgi Holdings, Inc. | Spinal implant with improved surface properties for delivery |
CA2643859A1 (en) * | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
JPWO2008023720A1 (ja) | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
WO2008075172A2 (en) * | 2006-12-19 | 2008-06-26 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
WO2008121670A1 (en) | 2007-03-30 | 2008-10-09 | Sanofi-Aventis | Pyrimidine hydrazide compounds as pgds inhibitors |
GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
EA017842B1 (ru) * | 2008-03-04 | 2013-03-29 | Вернэлис (Р&Д) Лтд. | Производные азетидина и их применение |
US20110306597A1 (en) | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
WO2009153720A1 (en) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
WO2010024903A1 (en) * | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
PE20110843A1 (es) | 2008-09-22 | 2011-12-08 | Cayman Chem Co | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica |
JP5111657B2 (ja) * | 2009-03-09 | 2013-01-09 | 大鵬薬品工業株式会社 | プロスタグランジンd合成酵素を阻害するピペラジン化合物 |
WO2011043359A1 (ja) | 2009-10-06 | 2011-04-14 | 協和発酵キリン株式会社 | 芳香族複素環化合物を含有する医薬 |
BR112012007635B1 (pt) | 2009-10-08 | 2019-07-09 | Sanofi | Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação |
CN102712626B (zh) | 2010-01-22 | 2014-09-17 | 大鹏药品工业株式会社 | 具有pgds抑制作用的哌嗪化合物 |
MX2012013127A (es) * | 2010-05-13 | 2012-11-30 | Amgen Inc | Compuestos heteroariloxiheterociclilo como inhibidores pde10. |
AU2011253058A1 (en) * | 2010-05-13 | 2012-12-06 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
EP2592933B1 (en) * | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
PE20131377A1 (es) * | 2010-09-13 | 2013-11-30 | Novartis Ag | Triazina-oxadiazoles |
KR101400192B1 (ko) | 2010-12-31 | 2014-05-27 | 제일모직 주식회사 | 포지티브형 감광성 수지 조성물, 이를 사용하여 제조된 감광성 수지막 및 상기 감광성 수지막을 포함하는 반도체 소자 |
US9133164B2 (en) * | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
JP5925301B2 (ja) | 2011-05-23 | 2016-05-25 | サノフイ | N−アルキル基を含有するジュウテリウム化化合物の製造方法 |
WO2013074387A1 (en) * | 2011-11-14 | 2013-05-23 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
US9499533B2 (en) * | 2012-03-27 | 2016-11-22 | Shionogi & Co., Ltd. | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity |
TWI585088B (zh) * | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
EP2956441A4 (en) | 2013-02-18 | 2016-11-02 | Scripps Research Inst | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
WO2015179414A1 (en) | 2014-05-19 | 2015-11-26 | Merial, Inc. | Anthelmintic compounds |
TWI695831B (zh) * | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Crth2拮抗劑化合物及其用途 |
BR112017020900B1 (pt) * | 2015-03-30 | 2023-02-23 | Mission Therapeutics Limited | Compostos de 1-ciano-pirrolidina como inibidores de usp30 e seu uso, composição farmacêutica |
RU2018126105A (ru) | 2015-12-17 | 2020-01-17 | Астекс Терапьютикс Лимитед | Хинолин-3-карбоксамиды в качестве ингибиторов h-pgds |
JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
-
2017
- 2017-06-16 JO JOP/2019/0072A patent/JOP20190072A1/ar unknown
- 2017-10-11 UY UY0001037440A patent/UY37440A/es unknown
- 2017-10-11 TW TW106134668A patent/TW201827412A/zh unknown
- 2017-10-11 AR ARP170102843A patent/AR109931A1/es unknown
- 2017-10-12 BR BR112019007609A patent/BR112019007609A2/pt not_active Application Discontinuation
- 2017-10-12 MA MA046531A patent/MA46531A/fr unknown
- 2017-10-12 KR KR1020197013195A patent/KR20190072565A/ko not_active Application Discontinuation
- 2017-10-12 WO PCT/IB2017/056320 patent/WO2018069863A1/en unknown
- 2017-10-12 PE PE2019000741A patent/PE20191020A1/es unknown
- 2017-10-12 JP JP2019520150A patent/JP6938628B2/ja active Active
- 2017-10-12 EP EP17797738.6A patent/EP3526206A1/en not_active Withdrawn
- 2017-10-12 MX MX2019004320A patent/MX2019004320A/es unknown
- 2017-10-12 CN CN201780075127.1A patent/CN110072857A/zh active Pending
- 2017-10-12 AU AU2017342156A patent/AU2017342156B2/en not_active Ceased
- 2017-10-12 US US16/341,113 patent/US11053234B2/en active Active
- 2017-10-12 CA CA3038756A patent/CA3038756A1/en not_active Abandoned
- 2017-10-12 CR CR20190174A patent/CR20190174A/es unknown
- 2017-10-12 EA EA201990904A patent/EA201990904A1/ru unknown
-
2019
- 2019-03-25 IL IL265597A patent/IL265597A/en unknown
- 2019-03-26 ZA ZA2019/01848A patent/ZA201901848B/en unknown
- 2019-04-08 DO DO2019000087A patent/DOP2019000087A/es unknown
- 2019-04-08 CO CONC2019/0003482A patent/CO2019003482A2/es unknown
- 2019-04-11 CL CL2019000986A patent/CL2019000986A1/es unknown
- 2019-04-12 PH PH12019500811A patent/PH12019500811A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2019000087A (es) | 2019-06-16 |
EP3526206A1 (en) | 2019-08-21 |
CN110072857A (zh) | 2019-07-30 |
WO2018069863A1 (en) | 2018-04-19 |
AU2017342156A1 (en) | 2019-04-18 |
JP2019536757A (ja) | 2019-12-19 |
US20190241554A1 (en) | 2019-08-08 |
PH12019500811A1 (en) | 2020-01-20 |
CL2019000986A1 (es) | 2019-06-21 |
JP6938628B2 (ja) | 2021-09-22 |
KR20190072565A (ko) | 2019-06-25 |
TW201827412A (zh) | 2018-08-01 |
MX2019004320A (es) | 2019-06-12 |
CO2019003482A2 (es) | 2019-04-12 |
CA3038756A1 (en) | 2018-04-19 |
EA201990904A1 (ru) | 2019-08-30 |
JOP20190072A1 (ar) | 2019-04-07 |
US11053234B2 (en) | 2021-07-06 |
MA46531A (fr) | 2019-08-21 |
ZA201901848B (en) | 2021-01-27 |
IL265597A (en) | 2019-05-30 |
AU2017342156B2 (en) | 2020-10-22 |
CR20190174A (es) | 2019-08-21 |
PE20191020A1 (es) | 2019-07-18 |
UY37440A (es) | 2018-04-30 |
BR112019007609A2 (pt) | 2019-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109931A1 (es) | Compuesto inhibidor de la prostaglandina d sintasa hematopoyética (h-pgds), composición farmacéutica que lo comprende y uso del compuesto para fabricar un medicamento | |
SV2016005328A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
CO2018008759A2 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
CU20200051A7 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
AR106652A1 (es) | Compuestos para tratar la esclerosis lateral amiotrófica | |
AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
ECSP13012363A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica | |
CU20220005A7 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
UY32490A (es) | Inhibidores de beta-secretasa | |
ES2678086T3 (es) | Compuestos de diona cíclicos (alquil-fenil)-sustituidos activos como herbicidas y derivados de los mismos | |
AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
AR094929A1 (es) | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 | |
AR107030A1 (es) | Inhibidores aza-bencimidazol de pad4 | |
AR080859A1 (es) | Derivados 1,2,4 triazolo-piridinicos inhibidores no nucleosidicos de la transcriptasa inversa, utiles para tratar infecciones por vih y composiciones farmaceuticas que los contienen. | |
AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
MY169179A (en) | Novel piperidine compound or salt thereof | |
PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |